One day after the kidney is transplanted into the recipient, the donor stem cells engraft in the marrow of the recipient and give rise to other specialized blood cells, like immune cells. The goal is to create an environment where two bone marrow systems co-exist and function in one person. Following transplantation, the recipient takes anti-rejection drugs which are decreased over time with the goal to stop a year after the transplant.
In 1998, Ildstad was one of the first recruits to the University of Louisville under the Commonwealth's Bucks for Brains initiative, advanced by former Gov. Paul Patton. As the Jewish Hospital Distinguished Chair in Transplantation Research, Ildstad brought a team of 25 families from Philadelphia to join the University of Louisville. In the following years the team has continued to examine the facilitating cell (FCRx) platform technology for the treatment of kidney transplant recipients as well as considering its potential for the treatment of red blood cell disorders, inherited metabolic storage disorders of childhood, and autoimmune disorders.
"Being a transplant recipient is not easy. In order to prevent rejection, current transplant recipients must take multiple pills a day for the rest of their lives. These immunosuppressive medications come with serious side effects with prolonged use including high blood pressure, diabetes, infection, heart disease and cancer, as well as direct damaging effects to the organ transplant," Ildstad said. "This new approach would potentially offer a better quality of life and fewer health risks for transplant recipients."
"In 1997, the University of Louisville was given a mandate to become a premier metropolitan research university that transforms the lives of the people of Kentucky and beyond," sa
|Contact: Gary Mans|
University of Louisville